MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today ...
CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
– Abstract selected for oral presentation at 2026 American Thoracic Society International Conference – ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery ...
Dr. Shehnaaz Suliman is the new chief executive officer and member of the board of ReCode Therapeutics. Biopharmaceutical company ReCode Therapeutics announced today the appointment of Dr. Shehnaaz ...
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on. Benchmark your ...
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results